Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 6/20 | 0.44 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.44 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.44 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.44 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.44 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.44 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 8/20 | 0.42 |
| ▸ | MMP1 | P03956 | 2/20 | 0.42 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1168483 | 0.86 | MAPT (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL22115151 | 0.80 | STS (0.47) | STSPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1168984 | 0.78 | PSEN1 (0.54) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1168731 | 0.77 | PSEN1 (0.53) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1169307 | 0.76 | MMP13 (0.58) | STSMAPTKDM4EMMP13MMP1 | |
| SCHEMBL12863287 | 0.76 | MMP13 (0.58) | STSMAPTKDM4EMMP13MMP1 | |
| SCHEMBL4100013 | 0.75 | STS (0.69) | STSMAPTKDM4EMMP13MMP1 | |
| Hydrochloric Acid SCHEMBL1168554 | 0.75 | PSEN1 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL22089492 | 0.73 | STS (0.57) | STSPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL1563895 | 0.72 | ALDH1A1 (0.54) | STSPSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034513-A1 | Heterocyclic Sulfonamide Inhibitors of Beta Amyloid Production | WYETH LLC (US) | 2011-02-10 | — | — | US | disclosed |
| US-7842718-B2 | Heterocyclic sulfonamide inhibitors of beta amyloid production | WYETH LLC (US) | 2010-11-30 | — | — | US | disclosed |
| US-7691884-B2 | Heterocyclic sulfonamide inhibitors of β amyloid production | WYETH (US) | 2010-04-06 | — | — | US | disclosed |
| US-20100022594-A1 | HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION | WYETH (US) | 2010-01-28 | — | — | US | disclosed |
| EP-1341779-B1 | HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION | WYETH CORP (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050196813-A1 | Heterocyclic sulfonamide inhibitors of beta amyloid production | WYETH (US) | 2005-09-08 | — | — | US | disclosed |
| US-6878742-B2 | Heterocyclic sulfonamide inhibitors of beta amyloid production | WYETH (US) | 2005-04-12 | — | — | US | disclosed |
| US-20030229127-A1 | Heterocyclic sulfonamide inhibitors of beta amyloid production | WYETH | 2003-12-11 | — | — | US | disclosed |
| EP-1341779-A2 | HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION | Wyeth (US) | 2003-09-10 | — | — | EP | disclosed |
| US-6610734-B2 | For therapy of Alzheimer's Disease and Down's syndrome | WYETH | 2003-08-26 | — | — | US | disclosed |
| US-20020183361-A1 | Heterocyclic sulfonamide inhibitors of beta amyloid production | ARQULE | 2002-12-05 | — | — | US | disclosed |
| WO-2002057252-A2 | HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION | WYETH (US) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229127-A1 | Heterocyclic sulfonamide inhibitors of beta amyloid production | APP, BACE1, PSEN1 | STS 8/4885PSEN1 3/4885PSEN2 4/4885 |
| US-20100022594-A1 | HETEROCYCLIC SULFONAMIDE INHIBITORS OF BETA AMYLOID PRODUCTION | APP, BACE1, PSEN1 | STS 8/4885PSEN1 3/4885PSEN2 4/4885 |
| US-20110034513-A1 | Heterocyclic Sulfonamide Inhibitors of Beta Amyloid Production | APP, BACE1, PSEN1 | STS 8/4885PSEN1 3/4885PSEN2 4/4885 |
| US-20020183361-A1 | Heterocyclic sulfonamide inhibitors of beta amyloid production | APP, BACE1, PSEN1 | STS 8/4885PSEN1 3/4885PSEN2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.